Functional protease profiling for diagnosis of malignant disease

Proteomics - Clinical Applications

Volumn 6, Issue 1-2, 2012, Pages 60-78

  Findeisen, Peter ^a   Neumaier, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Profiling; Protease; Serum

Indexed keywords

ADAM10 ENDOPEPTIDASE; CASPASE 3; CASPASE 7; CASPASE 8; CATHEPSIN; CATHEPSIN D; CATHEPSIN H; CATHEPSIN X; COLLAGENASE 3; FURIN; GELATINASE A; GELATINASE B; HEPSIN; INTERSTITIAL COLLAGENASE; KALLIKREIN 5; KALLIKREIN 6; LEGUMAIN; MATRIPTASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 26; NEUROPSIN; NEUTROPHIL COLLAGENASE; PROTEINASE; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; STROMELYSIN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

CANCER CLASSIFICATION; CANCER PROGNOSIS; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME MODIFICATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY;

HUMANS; NEOPLASMS; PEPTIDE HYDROLASES; PEPTIDES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUBSTRATE SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84858969517     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100058     Document Type: Review

References (241)

1. Rosenblatt, K. P., Bryant-Greenwood, P., Killian, J. K.,Mehta, A. et al., Serum proteomics in cancer diagnosis and management. Annu. Rev. Med. 2004, 55, 97-112.
2. Baggerly, K., Morris, J., Coombes, K., Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20, 777-785.
3. Rifai, N., Gillette, M., Carr, S., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
4. Diamandis, E., Oncopeptidomics: a useful approach for cancer diagnosis? Clin. Chem. 2007, 53, 1004-1006.
5. Findeisen, P., Neumaier, M., Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin. Chem. Lab. Med. 2009, 47, 666-684.
6. Banks, R., Stanley, A., Cairns, D., Barrett, J. et al., Influences of blood sample processing on low-molecularweight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 2005, 51, 1637-1649.
7. Findeisen, P., Sismanidis, D., Riedl, M., Costina, V., Neumaier, M., Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2005, 51, 2409-2411.
8. Umemura, H., Nezu, M., Kodera, Y., Satoh, M. et al., Effects of the time intervals between venipuncture and serum preparation for serum peptidome analysis by matrixassisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta Int. J. Clin. Chem. 2009, 406, 179-180.
9. Karsan, A., Eigl, B., Flibotte, S., Gelmon, K. et al., Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 2005, 51, 1525-1528.
10. Semmes, O. J., Feng, Z., Adam, B.-L., Banez, L. L. et al., Evaluation of serum protein profiling by surfaceenhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 2005, 51, 102-112.
11. McLerran, D., Grizzle, W. E., Feng, Z., Bigbee, W. L. et al., Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin. Chem. 2008, 54, 44-52.
12. McLerran, D., Grizzle, W. E., Feng, Z., Thompson, I. M. et al., SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin. Chem. 2008, 54, 53-60.
13. Rai, A. J., Gelfand, C. A., Haywood, B. C., Warunek, D. J. et al., HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5, 3262-3277.
14. Hong, H., Dragan, Y., Epstein, J., Teitel, C. et al., Quality control and quality assessment of data from surfaceenhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics 2005, 6, S5.
15. Hu, J., Coombes, K., Morris, J., Baggerly, K., The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. Brief. Funct. Genomic. Proteomic. 2005, 3, 322-331.
16. Villanueva, J., Philip, J., Chaparro, C., Li, Y. et al., Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 2005, 4, 1060-1072.
17. Mischak, H., Apweiler, R., Banks, R., Conaway, M. et al., Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics - Clin. Appl. 2007, 1, 148-156.
18. Taylor, C., Paton, N., Lilley, K., Binz, P.-A. et al., The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 2007, 25, 887-893.
19. Koomen, J., Shih, L., Coombes, K., Li, D. et al., Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 2005, 11, 1110-1118.
20. Hortin, G., The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 2006, 52, 1223-1237.
21. Anderson, N., Anderson, N., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
22. Hoffman, S., Won, A. J., Echan, L., Speicher, D., Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J. Chromatogr. B 2007, 849, 43-52.
23. Lopez, M., Mikulskis, A., Kuzdzal, S., Golenko, E. et al., A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 2007, 53, 1067-1074.
24. Solassol, J., Marin, P., Demettre, E., Rouanet, P. et al., Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal. Biochem. 2005, 338, 26-31.
25. Omenn, G., Strategies for plasma proteomic profiling of cancers. Proteomics 2006, 6, 5662-5673.
26. Whiteaker, J., Zhang, H., Eng, J., Fang, R. et al., Headto-head comparison of serum fractionation techniques. J. Proteome Res. 2007, 6, 828-836.
27. Timms, J. F., Cramer, R., Camuzeaux, S., Tiss, A. et al., Peptides generated ex vivo from serum proteins by tumorspecific exopeptidases are not useful biomarkers in ovarian cancer. Clin. Chem. 2010, 56, 262-271.
28. Amon, L. M., Law, W., Fitzgibbon, M. P., Gross, J. A. et al., Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One 2010, 5, e11137.
29. Lee, H.-J., Lee, E.-Y., Kwon, M.-S., Paik, Y.-K., Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr. Opin. Chem. Biol. 2006, 10, 42-49.
30. Nedelkov, D., Kiernan, U. A., Niederkofler, E. E., Tubbs, K. A., Nelson, R. W., Investigating diversity in human plasma proteins. Proc. Natl. Acad. Sci. USA 2005, 102, 10852-10857.
31. Misek, D. E., Kuick, R., Wang, H., Galchev, V. et al., A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics 2005, 5, 3343-3352.
32. Doherty, N. S., Littman, B. H., Reilly, K., Swindell, A. C. et al., Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis. Electrophoresis 1998, 19, 355-363.
33. Rossi, L., Martin, B., Hortin, G., White, R. et al., Inflammatory protein profile during systemic high dose interleukin- 2 administration. Proteomics 2006, 6, 709-720.
34. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumorspecific serum peptidome patterns. J. Clin. Investig. 2006, 116, 271-284.
35. Ebert, M. P., Niemeyer, D., Deininger, S. O., Wex, T. et al., Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J. Proteome Res. 2006, 5, 2152-2158.
36. van den Broek, I., Sparidans, R. W., van Winden, A. W., Gast, M. C. et al., The absolute quantification of eight interalpha- trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics Clin. Appl. 2010, 4, 931-939.
37. Coussens, L., Werb, Z., Inflammation and cancer. Nature 2002, 420, 860-867.
38. Cazares, L., Diaz, J., Drake, R., Semmes, O., MALDI/SELDI protein profiling of serum for the identification of cancer biomarkers, in: Vlahou, A. (Ed.), Methods in Molecular Biology, vol. 428, Clinical Proteomics: Methods and Protocols, Humana Press, Totowa, NJ 2007, pp. 125-140.
39. Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A. et al., Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 2004, 76, 1560-1570.
40. Schlosser, G., Pocsfalvi, G., Huszar, E., Malorni, A., Hudecz, F., MALDI-TOF mass spectrometry of a combinatorial peptide library: effect of matrix composition on signal suppression. J. Mass Spectrom. 2005, 40, 1590-1594.
41. Annesley, T. M., Ion suppression in mass spectrometry. Clin. Chem. 2003, 49, 1041-1044.
42. Lin, S., Shaler, T. A., Becker, C. H., Quantification of intermediate-abundance proteins in serum by multiple reaction monitoring mass spectrometry in a single-quadrupole ion trap. Anal. Chem. 2006, 78, 762-5767.
43. van den Broek, I., Sparidans, R. W., Schellens, J. H., Beijnen, J. H., Specific investigation of sample handling effects on protease activities and absolute serum concentrations of various putative peptidome cancer biomarkers. Clin. Proteomics 2010, 6, 115-127.
44. Koomen, J. M., Li, D., Xiao, L. C., Liu, T. C. et al., Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 2005, 4, 972-981.
45. Fung, E., Yip, T.-T., Lomas, L., Wang, Z. et al., Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 2005, 115, 783-789.
46. Bakun, M., Karczmarski, J., Poznanski, J., Rubel, T. et al., An integrated LC-ESI-MS platform for quantitation of serum peptide ladders. Application for colon carcinoma study. Proteomics Clin. Appl. 2009, 3, 932-946.
47. Dekker, L. J., Burgers, P. C., Charif, H., van Rijswijk, A. L. et al., Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases. Proteomics 2010, 10, 2348-2358.
48. Lopez-Otin, C., Overall, C., Protease degradomics: A new challenge for proteomics. Nature reviews. Mol. Cell. Biol. 2002, 3, 509-519.
49. Yi, J., Liu, Z., Craft, D., O'Mullan, P. et al., Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. J. Proteome Res. 2008, 7, 5112-5118.
50. Marshall, J., Kupchak, P., Zhu, W., Yantha, J. et al., Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2003, 2, 361-372.
51. Findeisen, P., Peccerella, T., Post, S., Wenz, F., Neumaier, M., Spiking of serum specimens with exogenous reporter peptides for mass spectrometry based protease profiling as diagnostic tool. Rapid Commun. Mass Spectrom. 2008, 22, 1223-1229.
52. Peccerella, T., Lukan, N., Hofheinz, R., Schadendorf, D. et al., Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. Clin. Chem. 2010, 56, 272-280.
53. Kawakami, T., Hoshida, Y., Kanai, F., Tanaka, Y. et al., Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 2005, 5, 4287-4295.
54. Song, J., Patel, M., Rosenzweig, C. N., Chan-Li, Y. et al., Quantification of fragments of human serum inter-alphatrypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin. Chem. 2006, 52, 1045-1053.
55. Villanueva, J., Martorella, A., Lawlor, K., Philip, J. et al., Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 2006, 5, 1840-1852.
56. Escher, N., Kaatz, M., Melle, C., Hipler, C. et al., Posttranslational modifications of transthyretin are serummarkers in patients with mycosis fungoides. Neoplasia 2007, 9, 254-259.
57. Gericke, B., Raila, J., Sehouli, J., Haebel, S. et al., Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. Biomed. Chromatogr. Cancer 2005, 5, 133.
58. Ye, B., Cramer, D. W., Skates, S. J., Gygi, S. P. et al., Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 2003, 9, 2904-2911.
59. Paradis, V., Degos, F., Dargere, D., Pham, N. et al., Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005, 41, 40-47.
60. Wood, S. L., Rogers, M., Cairns, D. A., Paul, A. et al., Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br. J. Cancer 2010, 103, 101-111.
61. Li, J., Orlandi, R., White, C. N., Rosenzweig, J. et al., Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 2005, 51, 2229-2235.
62. Ye, B., Skates, S., Mok, S., Horick, N. et al., Proteomicbased discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12, 432-441.
63. Agnihotri, R., Crawford, H. C., Haro, H., Matrisian, L. M. et al., Osteopontin, a novel substrate for matrix metalloproteinase- 3 (stromelysin-1) and matrix metalloproteinase- 7 (matrilysin). J. Biol. Chem. 2001, 276, 28261-28267.
64. Fedarko, N. S., Jain, A., Karadag, A., Fisher, L. W., Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J. 2004, 18, 734-736.
65. Ward, D. G., Nyangoma, S., Joy, H., Hamilton, E. et al., Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. 2008, 6, 19.
66. Pisitkun, T., Johnstone, R., Knepper, M. A., Discovery of urinary biomarkers. Mol. Cell. Proteomics 2006, 5, 1760-1771.
67. Stix, B., Kahne, T., Sletten, K., Raynes, J. et al., Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases- 1, -2, and -3. Am. J. Pathol. 2001, 159, 561-570.
68. Rocken, C., Menard, R., Buhling, F., Vockler, S. et al., Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann. Rheum. Dis. 2005, 64, 808-815.
69. van der Hilst, J. C., Kluve-Beckerman, B., van der Meer, J. W., Simon, A., Cathepsin D activity protects against development of type AA amyloid fibrils. Eur. J. Clin. Investig. 2009, 39, 412-416.
70. Rawlings, N. D., Morton, F. R., Kok, C. Y., Kong, J., Barrett, A. J., MEROPS: the peptidase database. Nucleic Acids Res. 2008, 36, D320-D325.
71. Diamandis, E. P., Validation of breast cancer biomarkers identified by mass spectrometry. Clin. Chem. 2006, 52, 771-772; author reply 772.
72. Brown, J. E., Cook, R. J., Major, P., Lipton, A. et al., Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 2005, 97, 59-69.
73. Ylisirnio, S., Hoyhtya, M., Makitaro, R., Paaakko, P. et al., Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin. Cancer Res. 2001, 7, 1633-1637.
74. Yuan, C. X., Lasut, A. L., Wynn, R., Neff, N. T. et al., Purification of Her-2 extracellular domain and identification of its cleavage site. Protein Expr. Purif. 2003, 29, 217-222.
75. Liu, P. C., Liu, X., Li, Y., Covington, M. et al., Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol. Ther. 2006, 5, 657-664.
76. Witters, L., Scherle, P., Friedman, S., Fridman, J. et al., Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008, 68, 7083-7089.
77. Yang, Z., Harris, L. E., Palmer-Toy, D. E., Hancock, W. S., Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin. Chem. 2006, 52, 1897-1905.
78. Baechle, D., Sparbier, K., Dihazi, H., Blaschke, S. et al., Towards stable diagnostic setups in clinical proteomics: absolute quantitation of peptide biomarkers using MALDITOF- MS. Proteomics Clin. Appl. 2007, 1, 1280-1284.
79. Govorukhina, N. I., de Vries, M., Reijmers, T. H., Horvatovich, P. et al., Influence of clotting time on the protein composition of serum samples based on LC-MS data. J. Chromatogr. 2009, 877, 1281-1291.
80. Ransohoff, D. F., Gourlay, M. L., Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol. 2010, 28, 698-704.
81. Wimberger, P., Roth, C., Pantel, K., Kasimir-Bauer, S. et al., Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients. Int. J. Cancer 2011, 128, 2572-2580.
82. Chang, A., Scheer, M., Grote, A., Schomburg, I., Schomburg, D., BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Nucleic Acids Res. 2009, 37, D588-D592.
83. Quesada, V., Ordonez, G. R., Sanchez, L. M., Puente, X. S., Lopez-Otin, C., The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res. 2009, 37, D239-D243.
84. Gosalia, D. N., Salisbury, C. M., Ellman, J. A., Diamond, S. L., High throughput substrate specificity profiling of serine and cysteine proteases using solution-phase fluorogenic peptide microarrays. Mol. Cell. Proteomics 2005, 4, 626-636.
85. Stewart, N., Prieto, D., Cosentino, L., Issaq, H., Veenstra, T., The Approach and design of a surrogate protease substrate for disease biomarker discovery. Cell Preserv. Technol. 2007, 5, 205-215.
86. Findeisen, P., Post, S., Wenz, F., Neumaier, M., Addition of exogenous reporter peptides to serum samples before mass spectrometry-based protease profiling provides advantages over profiling of endogenous peptides. Clin. Chem. 2007, 53, 1864-1866.
87. Villanueva, J., Nazarian, A., Lawlor, K., Tempst, P., Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat. Protoc. 2009, 4, 1167-1183.
88. Lopez-Otin, C., Bond, J. S., Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283, 30433-30437.
89. Joyce, J. A., Pollard, J. W., Microenvironmental regulation of metastasis. Nat. Rev. 2009, 9, 239-252.
90. Egeblad, M., Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. 2002, 2, 161-174.
91. Lopez-Otin, C., Hunter, T., The regulatory crosstalk between kinases and proteases in cancer. Nat. Rev. 2010, 10, 278-292.
92. Mason, S. D., Joyce, J. A., Proteolytic networks in cancer. Trends Cell Biol. 2011, 21, 228-237.
93. Kessenbrock, K., Plaks, V., Werb, Z., Matrix metalloproteina ses: regulators of the tumor microenvironment. Cell 2010, 141, 52-67.
94. Duffy, M. J., McKiernan, E., O'Donovan, N., McGowan, P. M., Role of ADAMs in cancer formation and progression. Clin. Cancer Res. 2009, 15, 1140-1144.
95. Gocheva, V., Joyce, J. A., Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6, 60-64.
96. Emami, N., Diamandis, E. P., Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin. Chem. 2008, 54, 1600-1607.
97. McMahon, B., Kwaan, H. C., The plasminogen activator system and cancer. Pathophysiol. Haemost. Thromb. 2008, 36, 184-194.
98. Ghavami, S., Hashemi, M., Ande, S. R., Yeganeh, B. et al., Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 2009, 46, 497-510.
99. Stupack, D. G., Teitz, T., Potter, M. D., Mikolon, D. et al., Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006, 439, 95-99.
100. Lopez-Otin, C., Matrisian, L. M., Emerging roles of proteases in tumour suppression. Nat. Rev. 2007, 7, 800-808.
101. Brasse, D., Mathelin, C., Leroux, K., Chenard, M. P. et al., Matrix metalloproteinase 11/stromelysin-3 exerts both activator and repressor functions during the hematogenous metastatic process in mice. Int. J. Cancer 2010, 127, 1347-1355.
102. Overall, C. M., Kleifeld, O., Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 2006, 94, 941-946.
103. Fry, J. L., Toker, A., Secreted andmembrane-bound isoforms of protease ADAM9 have opposing effects on breast cancer cell migration. Cancer Res. 2010, 70, 8187-8198.
104. Gutwein, P., Mechtersheimer, S., Riedle, S., Stoeck, A. et al., ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB J. 2003, 17, 292-294.
105. Roy, R., Rodig, S., Bielenberg, D., Zurakowski, D., Moses, M. A., ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12- S protein in tumor metastasis. J. Biol. Chem. 2004, 286, 20758-20768.
106. Obeid, D., Nguyen, J., Lesavre, P., Bauvois, B., Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells. Oncogene 2007, 26, 102-110.
107. Kuroda, H., Mochizuki, S., Shimoda, M., Chijiiwa, M. et al., ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Int. J. Cancer 2010, 127, 1844-1856.
108. Gordon, S. G., Benson, B., Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb. Res. 1989, 56, 431-440.
109. Rucinska, M., Furman, M., Skrzydlewski, Z., Zaremba, E., Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Acta Biochim. Polonica 1997, 44, 109-112.
110. Roth, C., Kasimir-Bauer, S., Pantel, K., Schwarzenbach, H., Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol. Oncol. 2011, 5, 281-291.
111. Decock, J., Obermajer, N., Vozelj, S., Hendrickx, W. et al., Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int. J. Biol. Markers 2008, 23, 161-168.
112. Schweiger, A., Christensen, I. J., Nielsen, H. J., Sorensen, S. et al., Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int. J. Biol. Markers 2004, 19, 289-294.
113. Schweiger, A., Stabuc, B., Popovic, T., Turk, V., Kos, J., Enzyme-linked immunosorbent assay for the detection of total cathepsin H in human tissue cytosols and sera. J. Immunol. Methods 1997, 201, 165-172.
114. Laszlo, A., Sohar, I., Karacsonyi, S., Petri, A., Trojan, I., Activities of serum cathepsin (B, H and L) and metalloproteinase (MMP7-ase) in patients with gastrointestinal and bronchial malignant tumours. Acta Medica Hungarica 1990, 47, 107-109.
115. Sanchez-Martin, M. M., Cabezas, J. A., Ortega, S., Garcia, J. et al., Levels of serum cathepsin L and several glycosidases in patients operated for colorectal cancer. Cancer Lett. 1999, 141, 73-77.
116. Nishida, Y., Kohno, K., Kawamata, T., Morimitsu, K. et al., Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol. Oncol. 1995, 56, 357-361.
117. Warwas, M., Haczynska, H., Gerber, J., Nowak, M., Cathepsin B-like activity as a serum tumour marker in ovarian carcinoma. Eur. J. Clin. Chem. Clin. Biochem. 1997, 35, 301-304.
118. Szajda, S. D., Snarska, J., Jankowska, A., Roszkowska- Jakimiec, W. et al., Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients. Hepatogastroenterology 2008, 55, 388-393.
119. Wozniak, A., Mila-Kierzenkowska, C., Schachtschabel, D. O., Wozniak, B. et al., Activity of cathepsin D and alpha(1)-antitrypsin in the blood serum of patients with mammary carcinoma. Exp. Oncol. 2005, 27, 233-237.
120. Strojan, P., Budihna, M., Smid, L., Vrhovec, I., Skrk, J., Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck. Cancer Lett. 1998, 130, 49-56.
121. Fukuda, M. E., Iwadate, Y., Machida, T., Hiwasa, T. et al., Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005, 65, 5190-5194.
122. Merseburger, A. S., Hennenlotter, J., Stenzl, A., Beger, G. et al., Cathepsin D serum levels are not a valid serum marker in renal cell carcinoma. Urol. Int. 2007, 79, 41-43.
123. Wozniak, B., Mila-Kierzenkowska, C., Wozniak, A., Drewa, G. et al., The effect of combined therapy on activity of cathepsin D and alpha-1-antitrypsin in the blood serum of women with cervical cancer. Eur. J. Gynaecol. Oncol. 2008, 29, 617-619.
124. Sun, C., Su, K. H., Valentine, J., Rosa-Bauza, Y. T. et al., Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors. ACS Nano 2010, 4, 978-984.
125. Planque, C., Li, L., Zheng, Y., Soosaipillai, A. et al., A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin. Cancer Res. 2008, 14, 1355-1362.
126. Diamandis, E. P., Scorilas, A., Fracchioli, S., Van Gramberen, M. et al., Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J. Clin. Oncol. 2003, 21, 1035-1043.
127. El Sherbini, M. A., Sallam, M. M., Shaban, E. A., El-Shalakany, A. H., Diagnostic value of serum kallikreinrelated peptidases 6 and 10 versus CA125 in ovarian cancer. Int. J. Gynecol. Cancer 2011, 21, 625-632.
128. Kishi, T., Soosaipillai, A., Grass, L., Little, S. P. et al., Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin. Chem. 2004, 50, 709-716.
129. Luo, L. Y., Katsaros, D., Scorilas, A., Fracchioli, S. et al., The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003, 63, 807-811.
130. McIntosh, M. W., Liu, Y., Drescher, C., Urban, N., Diamandis, E. P., Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin. Cancer Res. 2007, 13, 4422-4428.
131. Nakamura, T., Scorilas, A., Stephan, C., Jung, K. et al., The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res. 2003, 63, 6543-6546.
132. Ochiai, A., Shukla, A., Davis, J. W., Fritsche, H. A. et al., Is there a role for serum human tissue kallikrein in detection of prostate cancer? Urology 2007, 70, 519-522.
133. Costa, L. A., Alho, I., Casimiro, S., Oliveira, A. G. et al., Markers of bone turnover (ICTP, NTX) and serum matrix metalloproteinase 1 (MMP1) as prognostic markers in breast cancer patients (BC) with bone metastases (BM) treated with bisphosphonates (BP). J. Clin. Oncol. 2008, 26, May 20 suppl, abstr 1024.
134. Tahara, K., Mimori, K., Iinuma, H., Iwatsuki, M. et al., Serum matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer. Ann. Surg. Oncol. 2010, 17, 3362-3369.
135. Somiari, S. B., Somiari, R. I., Heckman, C. M., Olsen, C. H. et al., Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int. J. Cancer 2006, 119, 1403-1411.
136. Somiari, S. B., Shriver, C. D., Heckman, C., Olsen, C. et al., Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 2006, 233, 98-107.
137. Leppa, S., Saarto, T., Vehmanen, L., Blomqvist, C., Elomaa, I., A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin. Cancer Res. 2004, 10, 1057-1063.
138. Daniele, A., Zito, A. F., Giannelli, G., Divella, R. et al., Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 2010, 30, 3521-3527.
139. Coskun, U., Yamac, D., Gulbahar, O., Sancak, B. et al., Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response? Neoplasma 2007, 54, 348-352.
140. Sheen-Chen, S. M., Chen, H. S., Eng, H. L., Sheen, C. C., Chen, W. J., Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett. 2001, 173, 79-82.
141. Jinga, D., Stefanescu, M., Blidaru, A., Condrea, I. et al., Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors. Roum. Arch. Microbiol. Immunol. 2004, 63, 141-158.
142. Acar, A., Onan, A., Coskun, U., Uner, A. et al., Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med. Oncol. (Northwood, London, England) 2008, 25, 279-283.
143. Gohji, K., Fujimoto, N., Komiyama, T., Fujii, A. et al., Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996, 78, 2379-2387.
144. Riedel, F., Gotte, K., Schwalb, J., Hormann, K., Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res. 2000, 20, 3045-3049.
145. Kuyvenhoven, J. P., van Hoek, B., Blom, E., van Duijn, W. et al., Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thromb. Haemost. 2003, 89, 718-725.
146. Yeh, H. C., Lin, S. M., Chen, M. F., Pan, T. L. et al., Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma. Hepatogastroenterology 2010, 57, 98-102.
147. Garzetti, G. G., Ciavattini, A., Lucarini, G., Goteri, G. et al., Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res. 1995, 15, 2799-2804.
148. Emara, M., Cheung, P. Y., Grabowski, K., Sawicki, G., Wozniak, M., Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers. Clin. Chem. Lab. Med. 2009, 47, 993-1000.
149. Yoshino, Y., Kageshita, T., Nakajima, M., Funakubo, M., Ihn, H., Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase- 1 and -2 in patients with malignant melanoma. J. Dermatol. 2008, 35, 206-214.
150. Baker, T., Tickle, S., Wasan, H., Docherty, A. et al., Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer 1994, 70, 506-512.
151. Leelawat, K., Sakchinabut, S., Narong, S., Wannaprasert, J., Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. Biomed. Chromatogr. Gastroenterol. 2009, 9, 30.
152. Leelawat, K., Narong, S., Wannaprasert, J., Ratanashu-ek, T., Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J. Gastroenterol. 2010, 16, 4697-4703.
153. Garcia-Albeniz, X., Pericay, C., Alonso-Espinaco, V., Alonso, V. et al., Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol. 2011, 32, 417-424.
154. Martinez-Fernandez, A., Garcia-Albeniz, X., Pineda, E., Visa, L. et al., Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann. Surg. Oncol. 2009, 16, 1412-1420.
155. Maurel, J., Nadal, C., Garcia-Albeniz, X., Gallego, R. et al., Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int. J. Cancer 2007, 121, 1066-1071.
156. Gallego, R., Codony-Servat, J., Garcia-Albeniz, X., Carcereny, E. et al., Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. Endocr. Relat. Cancer 2009, 16, 311-317.
157. Szarvas, T., Becker, M., Vom Dorp, F., Meschede, J. et al., Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int. J. Cancer 2011, 128, 1486-1492.
158. Kuropkat, C., Duenne, A. A., Herz, U., Renz, H., Werner, J. A., Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer. Neoplasma 2004, 51, 375-378.
159. Vihinen, P., Koskivuo, I., Syrjanen, K., Tervahartiala, T. et al., Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res. 2008, 18, 268-273.
160. Decock, J., Hendrickx, W., Vanleeuw, U., Van Belle, V. et al., Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. Biomed. Chromatogr. Cancer 2008, 8, 77.
161. Ranuncolo, S. M., Armanasco, E., Cresta, C., Bal De Kier Joffe, E., Puricelli, L., Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int. J. Cancer 2003, 106, 745-751.
162. Zucker, S., Lysik, R. M., Zarrabi, M. H., Moll, U., M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993, 53, 140-146.
163. Marcos, C. A., Martinez, D. A., de Los Toyos, J. R., Dominguez Iglesias, F. et al., The usefulness of new serum tumor markers in head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. 2009, 140, 375-380.
164. Laudanski, P., Swiatecka, J., Kozlowski, L., Lesniewska, M. et al., Increased serum level of membrane type 1-matrix metalloproteinase (MT1-MMP/MMP-14) in patients with breast cancer. Folia histochemica et cytobiologica 2010, 48, 101-103.
165. Taubert, H., Wurl, P., Greither, T., Kappler, M. et al., Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br. J. Cancer 2010, 102, 731-737.
166. Herszenyi, L., Farinati, F., Cardin, R., Istvan, G. et al., Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. Biomed. Chromatogr. Cancer 2008, 8, 194.
167. Strojan, P., Budihna, M., Smid, L., Vrhovec, I., Skrk, J., Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur. J. Cancer 1998, 34, 1193-1197.
168. Ljuca, D., Fatusic, Z., Iljazovic, E., Ahmetovic, B., Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn. J. Basic Med. Sci. 2007, 7, 111-116.
169. Cobos, E., Jumper, C., Lox, C., Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. Clin. Appl. Thromb. Hemost. 2003, 9, 241-246.
170. Miyake, H., Hara, I., Yamanaka, K., Gohji, K. et al., Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999, 39, 123-129.
171. Murakami, H., Yokoyama, A., Kondo, K., Nakanishi, S. et al., Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin. Cancer Res. 2005, 11, 8674-8679.
172. Kojima, K., Mihara, R., Sakai, T., Togari, A. et al., Serum activities of dipeptidyl-aminopeptidase II and dipeptidylaminopeptidase IV in tumor-bearing animals and in cancer patients. Biochem. Med. Metab. Biol. 1987, 37, 35-41.
173. Cordero, O. J., Salgado, F. J., Nogueira, M., On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol. Immunother. 2009, 58, 1723-1747.
174. Yoshii, Y., Kasugai, T., Kato, T., Nagatsu, T., Sakakibara, S., Changes in serum dipeptidyl-aminopeptidase IV (glycylprolyl dipeptidyl-aminopeptidase) activity of patients with gastric carcinoma after surgical excision and the enzyme activity in the carcinoma tissue. Biochem. Med. 1981, 25, 276-282.
175. Fukasawa, K., Harada, M., Komatsu, M., Yamaoka, M. et al., Serum dipeptidyl peptidase (DPP) IV activities in oral cancer patients. Int. J. Oral Surg. 1982, 11, 246-250.
176. Eric-Nikolic, A., Matic, I. Z., Ethordevic, M., Milovanovic, Z. et al., Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors. Immunobiology 2011, 216, 942-946.
177. Wild, N., Andres, H., Rollinger, W., Krause, F. et al., A combination of serum markers for the early detection of colorectal cancer. Clin. Cancer Res. 2010, 16, 6111-6121.
178. Murphy, G. P., Kenny, G. M., Ragde, H., Wolfert, R. L. et al., Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998, 51, 89-97.
179. Garg, L. N., Yadav, S. P., Lal, H., Serum leucine aminopeptidase in head and neck cancer. J. Laryngol. Otol. 1994, 108, 660-662.
180. Gupta, S. K., Aziz, M., Khan, A. A., Mohsin, S., Significance of serum leucine aminopeptidase in tumours of female genital tract. J. Indian Med. Assoc. 1989, 87, 68-70.
181. Aziz, M., Gupta, S. K., Khan, A. A., Serum leucine aminopeptidase profile in cancers of gastro-intestinal tract with special reference to hepatic metastasis. J. Ind. Med. Assoc. 1990, 88, 160-163.
182. Schomburg, I., Chang, A., Ebeling, C., Gremse, M. et al., BRENDA, the enzyme database: updates and major new developments. Nucleic Acids Res. 2004, 32, D431-D433.
183. Yan, L., Zucker, S., Toole, B. P., Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb. Haemost. 2005, 93, 199-204.
184. Lewis, C. E., Pollard, J. W., Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66, 605-612.
185. Ludwig, T., Local proteolytic activity in tumor cell invasion and metastasis. Bioessays 2005, 27, 1181-1191.
186. Jessani, N., Liu, Y., Humphrey, M., Cravatt, B. F., Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA 2002, 99, 10335-10340.
187. Nomura, D. K., Dix, M. M., Cravatt, B. F., Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. 2010, 10, 630-638.
188. Schmitt, M., Mengele, K., Napieralski, R., Magdolen, V. et al., Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 2010, 10, 1051-1067.
189. Lescuyer, P., Hochstrasser, D., Rabilloud, T., How shall we use the proteomics toolbox for biomarker discovery? J. Proteome Res. 2007, 6, 3371-3376.
190. Murnane, M. J., Cai, J., Shuja, S., McAneny, D. et al., Active MMP-2 effectively identifies the presence of colorectal cancer. Int. J. Cancer 2009, 125, 2893-2902.
191. Williams, S. A., Jelinek, C. A., Litvinov, I., Cotter, R. J. et al., Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate 2011.
192. Paduch, R., Kandefer-Szerszen, M., Expression and activation of proteases in co-cultures. Exp. Toxicol. Pathol. 2011, 63, 79-87.
193. Vukmirovic-Popovic, S., Escott, N. G., Duivenvoorden, W. C., Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples. Oncol. Rep. 2008, 20, 897-903.
194. Witt, I., Test systems with synthetic peptide substrates in haemostaseology. Eur. J. Clin. Chem. Clin. Biochem. 1991, 29, 355-374.
195. Villanueva, J., Nazarian, A., Lawlor, K., Yi, S. S. et al., A sequence-specific exopeptidase activity test (SSEAT) for ''functional'' biomarker discovery. Mol. Cell. Proteomics 2008, 7, 509-518.
196. Beekman, B., Drijfhout, J. W., Ronday, H. K., TeKoppele, J. M., Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin. Ann. NY Acad. Sci. 1999, 878, 150-158.
197. Sottrup-Jensen, L., Alpha-macroglobulins: Structure, shape, and mechanism of proteinase complex formation. J. Biol. Chem. 1989, 264, 11539-11542.
198. O'Mullan, P., Craft, D., Yi, J., Gelfand, C. A., Thrombin induces broad spectrum proteolysis in human serum samples. Clin. Chem. Lab. Med. 2009, 47, 685-693.
199. Niessen, S., Hoover, H., Gale, A. J., Proteomic analysis of the coagulation reaction in plasma and whole blood using PROTOMAP. Proteomics 2011, 11, 2377-2388.
200. Wildes, D., Wells, J. A., Sampling the N-terminal proteome of human blood. Proc. Natl. Acad. Sci. USA 2010, 107, 4561-4566.
201. Tempst, P., Response to ''Letter to the Editor'' by E.P. Diamandis, V. Kulasingam, G. Sardana., J. Clin. Investig. 2006, eletter http://www.jci.org/eletters/view/26022.
202. Overall, C. M., Blobel, C. P., In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell. Biol. 2007, 8, 245-257.
203. Diamond, S. L., Methods for mapping protease specificity. Curr. Opin. Chem. Biol. 2007, 11, 46-51.
204. Fields, G. B., The collagen triple-helix: correlation of conformation with biological activities. Connect. Tissue Res. 1995, 31, 235-243.
205. Schilling, O., Huesgen, P. F., Barre, O., Auf dem Keller, U., Overall, C. M., Characterization of the prime and nonprime active site specificities of proteases by proteomederived peptide libraries and tandem mass spectrometry. Nat. Protoc. 2011, 6, 111-120.
206. Doucet, A., Butler, G. S., Rodriguez, D., Prudova, A., Overall, C. M., Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol. Cell. Proteomics 2008, 7, 1925-1951.
207. Robinson, S., Niles, R. K., Witkowska, H. E., Rittenbach, K. J. et al., A mass spectrometry-based strategy for detecting and characterizing endogenous proteinase activities in complex biological samples. Proteomics 2008, 8, 435-445.
208. Verspurten, J., Gevaert, K., Declercq, W., Vandenabeele, P., SitePredicting the cleavage of proteinase substrates. Trends Biochem. Sci. 2009, 34, 319-323.
209. Rak, J., Yu, J. L., Luyendyk, J., Mackman, N., Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 2006, 66, 10643-10646.
210. Yepes, D., Jacob, A., Dauber, M., Costina, V. et al., Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: A new approach for diagnosis of malignant disease. Int. J. Oncol. 2011, 39, 145-154.
211. Yi, J., Kim, C., Gelfand, C. A., Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J. Proteome Res. 2007, 6, 1768-1781.
212. Koo, B. H., Park, M. Y., Jeon, O. H., Kim, D. S., Regulatory mechanism of matrix metalloprotease-2 enzymatic activity by factor Xa and thrombin. J. Biol. Chem. 2009, 284, 23375-23385.
213. Monea, S., Lehti, K., Keski-Oja, J., Mignatti, P., Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell. Physiol. 2002, 192, 160-170.
214. Hahn-Dantona, E., Ramos-DeSimone, N., Sipley, J., Nagase, H. et al., Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann. NY Acad. Sci. 1999, 878, 372-387.
215. Mannello, F., Tonti, G. A., Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int. J. Cancer 2007, 121, 216-218; author reply 219-223.
216. Jung, K., Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy. Br. J. Cancer 2008, 99, 553-554; author reply 555.
217. Castellazzi, M., Tamborino, C., Fainardi, E., Manfrinato, M. C. et al., Effects of anticoagulants on the activity of gelatinases. Clin. Biochem. 2007, 40, 1272-1276.
218. Guder, W., Use of anticoagulants in diagnostic laboratory investigations and Stability of blood, plasma and serum samples. WHO/DIL/LAB/99.1 Rev.2 2002.
219. Consolo, M., Amoroso, A., Spandidos, D. A., Mazzarino, M. C., Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int. J. Mol. Med. 2009, 24, 143-152.
220. Peracaula, R., Sarrats, A., Rudd, P. M., Liver proteins as sensor of human malignancies and inflammation. Proteomics Clin. Appl. 2010, 4, 426-431.
221. Ransohoff, D. F., Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 2005, 5, 142-149.
222. Ioannidis, J. P., A roadmap for successful applications of clinical proteomics. Proteomics Clin. Appl. 2011, 5, 241-247.
223. Bossuyt, P., Reitsma, J., Bruns, D., Gatsonis, C. et al., The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem. 2003, 49, 7-18.
224. Mischak, H., Apweiler, R., Banks, R., Conaway, M. et al., Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin. Appl. 2007, 1, 148-156.
225. Hanash, S., It takes a village to develop biomarkers. J. Proteome Res. 2007, 6, 3362.
226. Szajli, E., Feher, T., Medzihradszky, K. F., Investigating the quantitative nature of MALDI-TOF MS. Mol. Cell. Proteomics 2008, 7, 2410-2418.
227. Sandin, M., Krogh, M., Hansson, K., Levander, F., Generic workflow for quality assessment of quantitative label-free LC-MS analysis. Proteomics 2011, 11, 1114-1124.
228. Lin, T. S., Chiou, S. H., Wang, L. S., Huang, H. H. et al., Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol. Rep. 2004, 12, 717-723.
229. Bok, R. A., Hansell, E. J., Nguyen, T. P., Greenberg, N. M. et al., Patterns of protease production during prostate cancer progression: proteomic evidence for cascades in a transgenic model. Prostate Cancer Prostatic Dis. 2003, 6, 272-280.
230. Sun, H., Panicker, R. C., Yao, S. Q., Activity based fingerprinting of proteases using FRET peptides. Biopolymers 2007, 88, 141-149.
231. Kozlov, I. A., Melnyk, P. C., Hachmann, J. P., Srinivasan, A. et al., A high-complexity, multiplexed solution-phase assay for profiling protease activity on microarrays. Comb. Chem. High Throughput Screen. 2008, 11, 24-35.
232. Kim, D. H., Shin, D. S., Lee, Y. S., Spot arrays on modified glass surfaces for efficient SPOT synthesis and on-chip bioassay of peptides. J. Pept. Sci. 2007, 13, 625-633.
233. Li, J., Yao, S. Q., ''Singapore Green'': A new fluorescent dye for microarray and bioimaging applications. Org. Lett. 2009, 11, 405-408.
234. Collet, B. Y., Nagashima, T., Yu, M. S., Pohl, N. L., Fluorous- based peptide microarrays for protease screening. J. Fluorine Chem. 2009, 130, 1042-1048.
235. Puig-Costa, M., Oliveras-Ferraros, C., Flaquer, S., Llopis- Puigmarti, F. et al., Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma. J. Surg. Oncol. 2011, 104, 106-109.
236. Blum, G., von Degenfeld, G., Merchant, M. J., Blau, H. M., Bogyo, M., Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activitybased probes. Nat. Chem. Biol. 2007, 3, 668-677.
237. LeBeau, A. M., Banerjee, S. R., Pomper, M. G., Mease, R. C., Denmeade, S. R., Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorg. Med. Chem. 2009, 17, 4888-4893.
238. Patterson, A. W., Wood, W. J., Ellman, J. A., Substrate activity screening (SAS): a general procedure for the preparation and screening of a fragment-based nonpeptidic protease substrate library for inhibitor discovery. Nat. Protoc. 2007, 2, 424-433.
239. Palermo, C., Joyce, J. A., Cysteine cathepsin proteases as pharmacological targets in cancer. Trend Pharmacol. Sci. 2008, 29, 22-28.
240. Overall, C. M., Kleifeld, O., Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. 2006, 6, 227-239.
241. Devel, L., Czarny, B., Beau, F., Georgiadis, D. et al., Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1' cavity. Biochimie 2010, 92, 1501-1508.